<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00208468</url>
  </required_header>
  <id_info>
    <org_study_id>CT99/02</org_study_id>
    <nct_id>NCT00208468</nct_id>
  </id_info>
  <brief_title>A Randomised Multi-centre Study to Compare the Long-term Performance of the Future Hip to 3 Other Implants in Primary Total Hip Replacement</brief_title>
  <official_title>A Multi-centre, Randomised, Parallel Group, Controlled Study to Compare the Performance of the Future Hip Against Three Currently Used Implants in Total Hip Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DePuy International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DePuy International</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This post-market clinical follow-up study was designed to compare hip replacement outcomes of
      the European Hip against 3 controls (Omniflex, Zweymuller, and Spotorno), however Omniflex
      did not end up being used. The first patient had surgery on February 18, 2000 and the final
      patient had surgery on September 2, 2005. There were 317 subjects consented but only 301 had
      hip replacement surgery (subjects received: 220 European hips, 33 Zweymuller, and 48
      Spotorno). The study took place at three sites. Each site used their standard device as the
      control. The Austrian site enrolled 69 European hips and 33 Zweymuller hips. 92 European hips
      and 48 Spotorno hips were enrolled in Germany. Finally, the site in Italy enrolled 59
      European hips. Although the study protocol intended collecting DEXA and RSA outcomes, the
      data collected by the sites did not include these outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment, investigators not wishing to continue with randomisation and a decision to
    rationalise this product from the Sponsors portfolio.
  </why_stopped>
  <start_date>February 2000</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Compare Survivorship estimates between subjects receiving the European, Spotorno, and Zweymuller hip devices through the 2 year follow-up period.</measure>
    <time_frame>2yrs post-surgery</time_frame>
    <description>Kaplan Meier survivorship analysis estimates the proportion of a population that will survive past a certain time avoiding a certain event. In this study, the event is removal of any component for any reason, also known as revision for any reason.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implant survivorship at 5 and 10 years.</measure>
    <time_frame>5 &amp; 10 year post-op</time_frame>
    <description>This post market study was terminated early; therefore the 5 and 10 year data was not collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare Harris Hip Scores between subjects receiving the European, Spotorno, and Zweymuller hip devices.</measure>
    <time_frame>3 Months post-op</time_frame>
    <description>The Harris Hip score is a 0-100 point score (where 100 indicates excellent hip condition) assessing pain, function, range of motion, and absence of deformity, of the affected hip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare Harris Hip scores between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>6 Months post-op</time_frame>
    <description>The Harris Hip score is a 0-100 point score (where 100 indicates excellent hip condition) assessing pain, function, range of motion, and absence of deformity, of the affected hip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare Harris Hip Scores between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>12 months post-op</time_frame>
    <description>The Harris Hip score is a 0-100 point score (where 100 indicates excellent hip condition) assessing pain, function, range of motion, and absence of deformity, of the affected hip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare Harris Hip scores between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>24 months post-op</time_frame>
    <description>The Harris Hip Score is a 0-100 point score (where 100 indicates excellent hip condition) assessing pain, function, range of motion, and absence of deformity, of the affected hip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare Harris Hip Scores between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>5 &amp; 10 years post-op</time_frame>
    <description>This post market study was terminated early; therefore the 5 and 10 year data was not collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare Oxford Hip Scores between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>3 months post-op</time_frame>
    <description>The Oxford Knee Score (OKS) is a 12 to 60 patient recorded outcome (PRO) score (where 12 indicates the best outcome) that evaluates pain and function of the affected hip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare Oxford Hip Scores between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>6 months post-op</time_frame>
    <description>The Oxford Knee Score (OKS) is a 12 to 60 patient recorded outcome (PRO) score (where 12 indicates the best outcome) that evaluates pain and function of the affected hip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare Oxford Hip Scores between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>12 months post-op</time_frame>
    <description>The Oxford Knee Score (OKS) is a 12 to 60 patient recorded outcome (PRO) score (where 12 indicates the best outcome) that evaluates pain and function of the affected hip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare Oxford Hip Scores between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>24 months post-op</time_frame>
    <description>he Oxford Knee Score (OKS) is a 12 to 60 patient recorded outcome (PRO) score (where 12 indicates the best outcome) that evaluates pain and function of the affected hip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare Oxford Hip Scores between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>5&amp; 10 years post-op</time_frame>
    <description>This post market study was terminated early; therefore the 5 &amp; 10 year data was not collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Radiolucent Zone(s) - Femur: To compare Progressive Radiolucent Zone(s) incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>3 months post-op</time_frame>
    <description>Width of lucency increases over time or expands lengthwise (into neighboring zones).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Radiolucent Zone(s) - Femur: To compare Progressive Radiolucent Zone(s) incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>6 months post-op</time_frame>
    <description>Width of lucency increases over time or expands lengthwise (into neighboring zones).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Radiolucent Zone(s) - Femur: To compare Progressive Radiolucent Zone(s) incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Width of lucency increases over time or expands lengthwise (into neighboring zones).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Radiolucent Zone(s) - Femur: To compare Progressive Radiolucent Zone(s) incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>24 months post-op</time_frame>
    <description>Width of lucency increases over time or expands lengthwise (into neighboring zones).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Radiolucent Zone(s) - Femur: To compare Progressive Radiolucent Zone(s) incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>5 &amp; 10 years post-op</time_frame>
    <description>This post market study was terminated early; therefore the 5 &amp; 10 year data was not collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Radiolucent Zone(s) - Acetabulum: To compare Progressive Radiolucent Zone(s) incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>3 months post-op</time_frame>
    <description>Width of lucency increases over time or expands lengthwise (into neighboring zones).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Radiolucent Zone(s) - Acetabulum: To compare Progressive Radiolucent Zone(s) incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>6 month post-op</time_frame>
    <description>Width of lucency increases over time or expands lengthwise (into neighboring zones).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Radiolucent Zone(s) - Acetabulum: To compare Progressive Radiolucent Zone(s) incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Width of lucency increases over time or expands lengthwise (into neighboring zones).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Radiolucent Zone(s) - Acetabulum: To compare Progressive Radiolucent Zone(s) incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>24 months post-op</time_frame>
    <description>Width of lucency increases over time or expands lengthwise (into neighboring zones).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Radiolucent Zone(s) - Acetabulum: To compare Progressive Radiolucent Zone(s) incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>5 &amp; 10 year post-op</time_frame>
    <description>This post-market study was terminated early; therefore the 5 &amp; 10 year data was not collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migration - Femoral: To compare Progressive Migration incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>3 months post-op</time_frame>
    <description>Component moves away, continuously over time, from its immediate post-operative position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migration - Femoral: To compare Progressive Migration incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>6 months post-op</time_frame>
    <description>Component moves away, continuously over time, from its immediate post-operative position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migration - Femoral: To compare Progressive Migration incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Component moves away, continuously over time, from its immediate post-operative position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migration - Femoral: To compare Progressive Migration incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>24 months post-op</time_frame>
    <description>Component moves away, continuously over time, from its immediate post-operative position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migration - Femoral: To compare Progressive Migration incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>5 &amp; 10 years post-op</time_frame>
    <description>This study was terminated early; therefore the 5 &amp; 10 year data was not collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migration - Acetabular: To compare Progressive Migration between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>3 months post-op</time_frame>
    <description>Component moves away, continuously over time, from its immediate post-operative position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migration - Acetabular: To compare Progressive Migration between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>6 months post-op</time_frame>
    <description>Component moves away, continuously over time, from its immediate post-operative position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migration - Acetabular: To compare Progressive Migration between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Component moves away, continuously over time, from its immediate post-operative position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migration - Acetabular: To compare Progressive Migration between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>24 months post-op</time_frame>
    <description>Component moves away, continuously over time, from its immediate post-operative position</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migration - Acetabular: To compare Progressive Migration between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>5 &amp; 10 years post-op</time_frame>
    <description>This post market study was terminated early; therefore the 5 &amp; 10 year data was not collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Osteolysis - Femur: To compare Progressive Osteolysis incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>3 months post-op</time_frame>
    <description>Component moves away, continuously over time, from its immediate post-operative position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Osteolysis - Femur: To compare Progressive Osteolysis incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>6 months post-op</time_frame>
    <description>Component moves away, continuously over time, from its immediate post-operative position</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Osteolysis - Femur: To compare Progressive Osteolysis incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Component moves away, continuously over time, from its immediate post-operative position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Osteolysis - Femur: To compare Progressive Osteolysis incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>24 months post-op</time_frame>
    <description>Component moves away, continuously over time, from its immediate post-operative position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Osteolysis - Femur: To compare Progressive Osteolysis incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>5 &amp; 10 years post-op</time_frame>
    <description>This post market study was terminated early; therefore the 5 &amp; 10 year data was not collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Osteolysis - Acetabulum: To compare Progressive Osteolysis incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>3 months post-op</time_frame>
    <description>Component moves away, continuously over time, from its immediate post-operative position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Osteolysis - Acetabulum: To compare Progressive Osteolysis incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>6 months post-op</time_frame>
    <description>Component moves away, continuously over time, from its immediate post-operative position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Osteolysis - Acetabulum: To compare Progressive Osteolysis incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Component moves away, continuously over time, from its immediate post-operative position</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Osteolysis - Acetabulum: To compare Progressive Osteolysis incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>24 months post-op</time_frame>
    <description>Component moves away, continuously over time, from its immediate post-operative position</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Osteolysis - Acetabulum: To compare Progressive Osteolysis incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>5 &amp; 10 years post-op</time_frame>
    <description>This post market study was terminated early; therefore the 5 &amp; 10 year data was not collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trochanteric Non-Union - Femur: To compare Trochanteric Non-union incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>3 months post-op</time_frame>
    <description>Trochanter portion of the bone does not heal correctly to proximal portion of the femoral shaft. Typically, after 6 months the lack of correct healing is classified as a 'non-union'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trochanteric Non-Union - Femur: To compare Trochanteric Non-union incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>6 months post-op</time_frame>
    <description>Trochanter portion of the bone does not heal correctly to proximal portion of the femoral shaft. Typically, after 6 months the lack of correct healing is classified as a 'non-union'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trochanteric Non-Union - Femur: To compare Trochanteric Non-union incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Trochanter portion of the bone does not heal correctly to proximal portion of the femoral shaft. Typically, after 6 months the lack of correct healing is classified as a 'non-union'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trochanteric Non-Union - Femur: To compare Trochanteric Non-union incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>24 months post-op</time_frame>
    <description>Trochanter portion of the bone does not heal correctly to proximal portion of the femoral shaft. Typically, after 6 months the lack of correct healing is classified as a 'non-union'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trochanteric Non-Union - Femur: To compare Trochanteric Non-union incidence between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>5 &amp; 10 years post-op</time_frame>
    <description>This post market study was terminated early; therefore the 5 &amp; 10 year data was not collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare Femoral Stem Orientation between subjects receiving the European, Spotorno, and Zweymuller hip devices.</measure>
    <time_frame>3 months post-op</time_frame>
    <description>Alignment is classified into 1 of 3 categories - Neutral, Varus (distal tip of stem lateral to mid-line of femur), or Valgus (distal tip of stem medial to mid-line of femur).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare Femoral Stem Orientation between subjects receiving the European, Spotorno, and Zweymuller hip devices.</measure>
    <time_frame>6 months post-op</time_frame>
    <description>Alignment is classified into 1 of 3 categories - Neutral, Varus (distal tip of stem lateral to mid-line of femur), or Valgus (distal tip of stem medial to mid-line of femur).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare Femoral Stem Orientation between subjects receiving the European, Spotorno, and Zweymuller hip devices.</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Alignment is classified into 1 of 3 categories - Neutral, Varus (distal tip of stem lateral to mid-line of femur), or Valgus (distal tip of stem medial to mid-line of femur).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare Femoral Stem Orientation between subjects receiving the European, Spotorno, and Zweymuller hip devices.</measure>
    <time_frame>24 months post-op</time_frame>
    <description>Alignment is classified into 1 of 3 categories - Neutral, Varus (distal tip of stem lateral to mid-line of femur), or Valgus (distal tip of stem medial to mid-line of femur).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare Femoral Stem Orientation between subjects receiving the European, Spotorno, and Zweymuller hip devices.</measure>
    <time_frame>5 &amp; 10 years post-op</time_frame>
    <description>This post market study was terminated early; therefore the 5 &amp; 10 year data was not collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare Brooker Ectopic Ossification between subjects receiving the European, Spotorno, and Zweymuller hip devices.</measure>
    <time_frame>3 months post-op</time_frame>
    <description>Presented by Brooker in JBJS 55a: 1629-1632 (1973). Soft tissue or bone bridging causing immobilization in severe cases; categorized into classes I to IV with I being islands of bone around soft tissue, and IV representing ankylosis of the hip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare Brooker Ectopic Ossification between subjects receiving the European, Spotorno, and Zweymuller hip devices.</measure>
    <time_frame>6 months post-op</time_frame>
    <description>Presented by Brooker in JBJS 55a: 1629-1632 (1973). Soft tissue or bone bridging causing immobilization in severe cases; categorized into classes I to IV with I being islands of bone around soft tissue, and IV representing ankylosis of the hip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare Brooker Ectopic Ossification between subjects receiving the European, Spotorno, and Zweymuller hip devices.</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Presented by Brooker in JBJS 55a: 1629-1632 (1973). Soft tissue or bone bridging causing immobilization in severe cases; categorized into classes I to IV with I being islands of bone around soft tissue, and IV representing ankylosis of the hip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare Brooker Ectopic Ossification between subjects receiving the European, Spotorno, and Zweymuller hip devices.</measure>
    <time_frame>24 months post-op</time_frame>
    <description>Presented by Brooker in JBJS 55a: 1629-1632 (1973). Soft tissue or bone bridging causing immobilization in severe cases; categorized into classes I to IV with I being islands of bone around soft tissue, and IV representing ankylosis of the hip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare Brooker Ectopic Ossification between subjects receiving the European, Spotorno, and Zweymuller hip devices.</measure>
    <time_frame>5 &amp; 10 years post-op</time_frame>
    <description>This post market study was terminated early; therefore the 5 &amp; 10 year data was not collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare Acetabular Socket Wear between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>3 months post-op</time_frame>
    <description>Linear wear, measured in millimeters (mm) of the femoral head into the acetabular socket.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare Acetabular Socket Wear between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>6 months post-op</time_frame>
    <description>Linear wear, measured in millimeters (mm) of the femoral head into the acetabular socket.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare Acetabular Socket Wear between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Linear wear, measured in millimeters (mm) of the femoral head into the acetabular socket</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare Acetabular Socket Wear between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>24 months post-op</time_frame>
    <description>Linear wear, measured in millimeters (mm) of the femoral head into the acetabular socket.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare Acetabular Socket Wear between subjects receiving the European, Spotorno, and Zweymuller hip devices</measure>
    <time_frame>5 &amp; 10 years post-op</time_frame>
    <description>This post market study was terminated early; therefore the 5 &amp; 10 year data was not collected</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">317</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Post-traumatic Arthritis</condition>
  <condition>Collagen Disorders</condition>
  <condition>Avascular Necrosis</condition>
  <condition>Traumatic Femoral Fractures</condition>
  <condition>Nonunion of Femoral Fractures</condition>
  <condition>Congenital Hip Dysplasia</condition>
  <condition>Slipped Capital Femoral Epiphysis</condition>
  <condition>Perthes Disease</condition>
  <arm_group>
    <arm_group_label>European Hip</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A cementless femoral component for use in total hip replacement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zweym체ller</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A cementless femoral component for use in total hip replacement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLS Spotorno</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A cementless femoral component for use in total hip replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>European Hip</intervention_name>
    <description>A cementless femoral component for use in total hip replacement</description>
    <arm_group_label>European Hip</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zweym체ller</intervention_name>
    <description>A cementless femoral component for use in total hip replacement</description>
    <arm_group_label>Zweym체ller</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CLS Spotorno</intervention_name>
    <description>A cementless femoral component for use in total hip replacement</description>
    <arm_group_label>CLS Spotorno</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        i) Administrative - The subject is able to understand the study, is willing to give
        voluntary, written, informed consent, will co-operate with assessment procedures and is
        geographically able to comply with the post-operative follow-up regime.

        ii) Age - The subject's age is between 18 and 75 years inclusive.

        iii) Sex - Male or female subjects may be recruited to the study.

        iv) Diagnosis -Subjects must be undergoing primary THR surgery for non-inflammatory
        degenerative joint disease including osteoarthritis, avascular necrosis, post-traumatic
        arthritis, fractured neck of femur and non-union of fractured neck of femur, SUFE or
        Perthes disease.

        v) Suitability - Subjects who in the opinion of the Investigator are considered to be
        suitable for treatment with the devices involved in the study.

        Exclusion Criteria:

        i) Subjects undergoing revision procedure to the operative hip.

        ii) Subjects who have had a previous femoral osteotomy to the operative hip.

        iii) Subjects who have a history of active sepsis in the joint.

        iv) Subjects who have been diagnosed with primary or secondary carcinomas in the last five
        years (excluding basal cell carcinoma or cervical carcinoma).

        v) Subjects with any condition which may, in the opinion of the Investigator, interfere
        with the total hip replacement's survival or outcome, e.g. Paget's disease, Charcot's
        disease.

        vi) Subjects with psycho-social disorders which, in the opinion of the Investigator would
        limit rehabilitation.

        vii) Subject's whose weight is &gt; 100kg.

        viii) Subjects with femoral head necrosis on the non-operated side (RSA and DEXA subjects
        only).

        ix) Subjects who have a fracture of the femur &gt; 6 months old (RSA and DEXA subjects only).

        x) Subjects diagnosed as having ankylosing spondylitis (RSA and DEXA subjects only)

        xi) Subjects with a known history of poor compliance to medical treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Univ. Kliniken</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univesit채tsklinikum Jena</name>
      <address>
        <city>Eisenberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InstitutoAzienda Gaetano Pini</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>October 6, 2016</last_update_submitted>
  <last_update_submitted_qc>October 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hip</keyword>
  <keyword>Cementless</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Femoral Fractures</mesh_term>
    <mesh_term>Hip Dislocation</mesh_term>
    <mesh_term>Hip Dislocation, Congenital</mesh_term>
    <mesh_term>Slipped Capital Femoral Epiphyses</mesh_term>
    <mesh_term>Legg-Calve-Perthes Disease</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

